Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.
about
Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis CEfficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-AnalysisA Novel Agonist of the TRIF Pathway Induces a Cellular State Refractory to Replication of Zika, Chikungunya, and Dengue Viruses.Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development.Interferons: Success in anti-viral immunotherapy.Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry.Management of hepatitis C in patients with chronic kidney disease.Protracted anaphylaxis developed after peginterferon α-2a administration for chronic hepatitis C.Hepatitis C in hemodialysis patientsA case of classic neuromyelitis optica (Devic's syndrome) triggered by pegylated-interferon αRegulation of cell growth by Notch signaling and its differential requirement in normal vs. tumor-forming stem cells in DrosophilaQuality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort.How hepatitis C patients manage the treatment process of pegylated interferon and ribavirin therapy: a qualitative study.Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study.Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study.Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in KoreaCurrent and emerging antiviral treatments for hepatitis C infectionAutoimmune thyroid disorders in hepatitis C virus infection: Effect of interferon therapyA randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3.Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma.Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C.A real-world intention-to-treat analysis of a decade's experience of treatment of hepatitis C with interferon-based therapies.Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained countryImpact of hepatitis C treatment initiation on adherence to concomitant medications.Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations.A new era in the treatment of chronic hepatitis C infection.Peginterferon Lambda-1a, a New Therapeutic for Hepatitis C Infection, from Bench to Clinic.Improving access to treatment for patients with chronic hepatitis C through outreach.Add-on neurological benefits of antiviral therapy in HCV patients with chronic kidney disease - a nationwide cohort study.The role of HCV proteins on treatment outcomes.Universal screening for chronic hepatitis C virus.Hemoglobin during ribavirin-based HCV therapy is closely related to circulating levels of DHEA.Commentary: sofosbuvir for treatment of hepatitis C virus genotype 2 or 3 infection in patients without treatment options.Efficacy of Interferon-Free Therapies for Chronic Hepatitis C: A Systematic Review of All Randomized Clinical Trials.Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis.Pegylated interferon-α induced hypoferremia is associated with the immediate response to treatment in hepatitis C.Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1-4 and 6 in Myanmar: Real-world experience.Randomized trial of low-dose peginterferon α-2b plus low and escalating doses of ribavirin in older patients with chronic hepatitis C with high viral load genotype 1.Newer therapeutics for hepatitis C
P2860
Q24200189-0B788350-2BE4-4B02-A575-439B05A744C5Q28074783-2A495C87-898C-4743-BE68-AEE03C9848C4Q30145658-26C40046-C9C5-4961-BCEF-91199BAB0940Q31051529-6CF1A0AF-D681-408F-B60C-45AEB2123BDCQ34276038-2DBFC63A-2DC2-4C4E-B5EF-7634337E713AQ34908895-E6A3C1CE-0D6A-401F-AB71-2B710C295B02Q34932338-D6ECD885-24A3-46A8-8BB7-E47225545D29Q35152412-BAA5D033-7132-4F1A-9A6A-86BCEAFFE1C3Q35237329-DD6087CE-B391-4E63-8703-0D3E3A368E78Q35290680-97B83D7B-1381-44D3-9819-1B4F31A579CFQ35642076-7BC63B6A-021F-46E0-A10A-DBBC7738231BQ36063808-95E68707-E707-465F-832B-434F1F4610F0Q36073408-E5459149-C6D2-418D-848A-0CCD63CC8673Q36192804-BE209E86-F587-4962-87C2-7D2A8F5AB3EBQ36391682-3B432593-95D7-4916-9528-C4521F73BEF7Q36460249-F41DA361-88DD-40A4-8FA9-A159867452EDQ36729900-095331ED-3C6C-4D10-A8AE-B3F38B5B72ABQ36862264-43D72125-444D-4991-A151-56A63A8F9464Q37187994-244A2D25-6DEF-4815-B5F1-68BA55401139Q37195548-1D1CD1CE-E8F1-43BD-A118-E89EA6D34EB3Q37263865-B5134CAA-0289-411D-A01E-6B61888F38F0Q37279260-534BB1B2-1CDC-412F-B427-CFC4FEB6D10BQ37349005-7734A30D-1227-45E7-B987-849FA4DA6402Q37424755-F58CED35-2B4F-4237-87DD-7E2298E91BBCQ37626270-F95E73AE-E558-4F3A-AFFD-398F101E0F22Q38002889-63CB1822-958C-44A3-A1B1-6E03DC4FEF0FQ38051248-033620B1-A489-49E7-9975-00FD28590BFFQ38584280-C402599D-7E8C-4237-9DB9-7A874A0D7EB4Q38609143-372F0F97-E8CC-4668-AA77-964EE98B93F3Q38621703-28AB9223-3DC0-4D8A-B208-B80BBE8EEBCDQ38668968-909CE258-355E-4D85-82E1-CC503F8D77E1Q38685582-46A45D1B-CFA5-4E48-A147-279B24995282Q38800419-DCAAB745-32E3-41D0-87C6-A1635BEAEED1Q38832988-AB0E4C9C-E454-4854-8B71-BA48F7E4C460Q38837174-D23E7A6F-5A31-4D44-983B-8B7D5DAB7D0BQ38903835-09A4F3A6-F26F-4A73-AB02-ED3E5D5BA57DQ39396566-6F13E953-3F0C-4512-91D7-B6D16609772CQ40213917-061F59A4-6642-4A90-BB7F-0FF19BA5BE8CQ40902801-983A3CC8-52BC-4C05-95B9-19D7FF5F2953Q40903024-D7B3B8DF-F863-48D4-B8EE-81B4D32803A5
P2860
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.
@en
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.
@nl
type
label
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.
@en
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.
@nl
prefLabel
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.
@en
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.
@nl
P2093
P2860
P356
P1476
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.
@en
P2093
Bela Hunyady
Cihan Yurdaydin
Curtis Cooper
Jidong Jia
Mark S Sulkowski
Mitchell L Shiffman
Olav Dalgard
Pavel Ogurtsov
P2860
P2888
P304
P356
10.1038/NRGASTRO.2011.21
P407
P577
2011-03-08T00:00:00Z